Financial Ratios 10x Genomics, Inc.
Equities
TXG
US88025U1097
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.46 USD | -0.02% |
|
-8.81% | +25.08% |
| 02-20 | UBS Adjusts Price Target on 10x Genomics to $20 From $14, Maintains Neutral Rating | MT |
| 02-12 | 10x Genomics, Inc., Q4 2025 Earnings Call, Feb 12, 2026 |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
Return on Assets | -3.4 | -10.25 | -12.22 | -12.77 | -6.4 | ||||
Return on Total Capital | -3.89 | -11.66 | -14.03 | -14.77 | -7.49 | ||||
Return On Equity % | -7.48 | -20.45 | -32.98 | -25.17 | -5.78 | ||||
Return on Common Equity | -7.48 | -20.45 | -32.98 | -25.17 | -5.78 | ||||
Margin Analysis | |||||||||
Gross Profit Margin % | 84.89 | 76.69 | 66.15 | 67.91 | 69.13 | ||||
SG&A Margin | 52.51 | 57.76 | 54.31 | 56.2 | 48.25 | ||||
EBITDA Margin % | -6.48 | -27.61 | -25.77 | -25.64 | -9.97 | ||||
EBITA Margin % | -10.79 | -32.52 | -31.51 | -31.51 | -15.6 | ||||
EBIT Margin % | -10.79 | -32.52 | -31.51 | -31.51 | -15.6 | ||||
Income From Continuing Operations Margin % | -11.87 | -32.14 | -41.23 | -29.9 | -6.77 | ||||
Net Income Margin % | -11.87 | -32.14 | -41.23 | -29.9 | -6.77 | ||||
Net Avail. For Common Margin % | -11.87 | -32.14 | -41.23 | -29.9 | -6.77 | ||||
Normalized Net Income Margin | -6.93 | -19.6 | -17.85 | -17.97 | -7.7 | ||||
Levered Free Cash Flow Margin | -13.66 | -18.45 | 4.95 | 9.79 | 23.08 | ||||
Unlevered Free Cash Flow Margin | -13.55 | -18.39 | 4.95 | 9.79 | 23.08 | ||||
Asset Turnover | |||||||||
Asset Turnover | 0.5 | 0.5 | 0.62 | 0.65 | 0.66 | ||||
Fixed Assets Turnover | 2.8 | 1.75 | 1.76 | 1.87 | 2.15 | ||||
Receivables Turnover (Average Receivables) | 7.19 | 5.45 | 5.65 | 6.03 | 9.53 | ||||
Inventory Turnover (Average Inventory) | 1.65 | 1.7 | 2.7 | 2.5 | 2.85 | ||||
Short Term Liquidity | |||||||||
Current Ratio | 6.77 | 4.85 | 4.69 | 4.97 | 4.46 | ||||
Quick Ratio | 6.1 | 4.08 | 3.96 | 4.09 | 3.95 | ||||
Operating Cash Flow to Current Liabilities | -0.19 | -0.26 | -0.12 | 0.06 | 0.89 | ||||
Days Sales Outstanding (Average Receivables) | 50.77 | 66.96 | 64.61 | 60.73 | 38.29 | ||||
Days Outstanding Inventory (Average Inventory) | 221.5 | 214.65 | 135.37 | 146.41 | 128.25 | ||||
Average Days Payable Outstanding | 38.67 | 50.04 | 33.82 | 25.52 | 27.26 | ||||
Cash Conversion Cycle (Average Days) | 233.6 | 231.57 | 166.16 | 181.62 | 139.28 | ||||
Long Term Solvency | |||||||||
Total Debt/Equity | 10.03 | 11.81 | 12.87 | 11.63 | 10.59 | ||||
Total Debt / Total Capital | 9.11 | 10.56 | 11.4 | 10.42 | 9.58 | ||||
LT Debt/Equity | 9.4 | 10.69 | 11.31 | 10.33 | 9.21 | ||||
Long-Term Debt / Total Capital | 8.54 | 9.56 | 10.02 | 9.25 | 8.33 | ||||
Total Liabilities / Total Assets | 19.75 | 21.69 | 23.22 | 22.7 | 23.53 | ||||
EBIT / Interest Expense | -61.1 | -352.82 | -5.91K | -48.11K | - | ||||
EBITDA / Interest Expense | -23.9 | -271.17 | -4.41K | -36.17K | - | ||||
(EBITDA - Capex) / Interest Expense | -140.85 | -547.77 | -5.89K | -39.27K | - | ||||
Total Debt / EBITDA | -3.96 | -0.74 | -0.65 | -0.57 | -1.65 | ||||
Net Debt / EBITDA | 24.42 | 2.59 | 2.01 | 2.15 | 8.58 | ||||
Total Debt / (EBITDA - Capex) | -0.67 | -0.37 | -0.49 | -0.53 | -1.48 | ||||
Net Debt / (EBITDA - Capex) | 4.14 | 1.28 | 1.51 | 1.98 | 7.69 | ||||
Growth Over Prior Year | |||||||||
Total Revenues, 1 Yr. Growth % | 64.13 | 5.28 | 19.81 | -1.28 | 5.25 | ||||
Gross Profit, 1 Yr. Growth % | 73.23 | -4.89 | 3.28 | 1.34 | 7.21 | ||||
EBITDA, 1 Yr. Growth % | -55.41 | 348.42 | 15.22 | -4.66 | -59.33 | ||||
EBITA, 1 Yr. Growth % | -37.99 | 217.4 | 19.06 | -3.65 | -48.16 | ||||
EBIT, 1 Yr. Growth % | -37.99 | 217.4 | 19.06 | -3.65 | -48.16 | ||||
Earnings From Cont. Operations, 1 Yr. Growth % | -89.27 | 185.11 | 53.67 | -28.41 | -76.16 | ||||
Net Income, 1 Yr. Growth % | -89.27 | 185.11 | 53.67 | -28.41 | -76.16 | ||||
Normalized Net Income, 1 Yr. Growth % | -35.37 | 197.88 | 11.98 | -3.23 | -55.15 | ||||
Diluted EPS Before Extra, 1 Yr. Growth % | -90.13 | 176.32 | 49.34 | -30.36 | -76.98 | ||||
Accounts Receivable, 1 Yr. Growth % | 66.49 | 22.24 | 10.19 | -23.49 | -46.49 | ||||
Inventory, 1 Yr. Growth % | 100.16 | 36.13 | -9.71 | 12.75 | -32.21 | ||||
Net Property, Plant and Equip., 1 Yr. Growth % | 92.29 | 55.9 | -3.97 | -10.15 | -7.35 | ||||
Total Assets, 1 Yr. Growth % | 9.63 | 1 | -6.2 | -4.82 | 13.36 | ||||
Tangible Book Value, 1 Yr. Growth % | 9.9 | -1.18 | -7.51 | -4.16 | 5.73 | ||||
Common Equity, 1 Yr. Growth % | 10.62 | -1.45 | -8.03 | -4.17 | 12.14 | ||||
Cash From Operations, 1 Yr. Growth % | -90.19 | 57.24 | -54.78 | -143.85 | 1.94K | ||||
Capital Expenditures, 1 Yr. Growth % | 176.22 | 30 | -63.09 | -74.5 | -52.11 | ||||
Levered Free Cash Flow, 1 Yr. Growth % | 232.19 | 42.17 | -133.05 | 116.54 | 150.66 | ||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 247.31 | 42.88 | -133.18 | 116.39 | 150.65 | ||||
Compound Annual Growth Rate Over Two Years | |||||||||
Total Revenues, 2 Yr. CAGR % | 41.23 | 31.45 | 12.31 | 8.75 | 1.93 | ||||
Gross Profit, 2 Yr. CAGR % | 50.08 | 28.36 | -0.85 | 2.3 | 4.2 | ||||
EBITDA, 2 Yr. CAGR % | 20.2 | 41.4 | 123.93 | 6.37 | -37.53 | ||||
EBITA, 2 Yr. CAGR % | 34.91 | 40.3 | 91.95 | 8.41 | -29.14 | ||||
EBIT, 2 Yr. CAGR % | 34.91 | 40.3 | 91.95 | 8.41 | -29.14 | ||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 36.49 | -44.7 | 109.32 | 4.89 | -58.68 | ||||
Net Income, 2 Yr. CAGR % | 36.49 | -44.7 | 109.32 | 4.89 | -58.68 | ||||
Normalized Net Income, 2 Yr. CAGR % | 35.69 | 38.75 | 80.25 | 5.5 | -34.24 | ||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -18.61 | -47.87 | 103.14 | 1.98 | -59.96 | ||||
Accounts Receivable, 2 Yr. CAGR % | 59.84 | 42.66 | 16.06 | -8.18 | -36.02 | ||||
Inventory, 2 Yr. CAGR % | 98.17 | 65.07 | 10.87 | 0.9 | -12.57 | ||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 117.24 | 73.14 | 22.35 | -7.11 | -8.76 | ||||
Total Assets, 2 Yr. CAGR % | 29.67 | 5.22 | -2.67 | -5.51 | 3.87 | ||||
Tangible Book Value, 2 Yr. CAGR % | 40.73 | 4.21 | -4.4 | -5.85 | 0.66 | ||||
Common Equity, 2 Yr. CAGR % | 39.51 | 4.41 | -4.8 | -6.12 | 3.66 | ||||
Cash From Operations, 2 Yr. CAGR % | -21.44 | -60.73 | -15.68 | -55.47 | 199.21 | ||||
Capital Expenditures, 2 Yr. CAGR % | 53.93 | 89.49 | -30.73 | -69.32 | -65.05 | ||||
Levered Free Cash Flow, 2 Yr. CAGR % | 42.75 | 117.32 | -32.4 | -19.65 | 131.76 | ||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 46.29 | 122.77 | -32.1 | -19.52 | 131.67 | ||||
Compound Annual Growth Rate Over Three Years | |||||||||
Total Revenues, 3 Yr. CAGR % | 49.66 | 28.06 | 27.45 | 7.59 | 7.57 | ||||
Gross Profit, 3 Yr. CAGR % | 49.33 | 28.91 | 19.41 | -0.13 | 3.89 | ||||
EBITDA, 3 Yr. CAGR % | 69.61 | 86.43 | 30.76 | 70.13 | -22.63 | ||||
EBITA, 3 Yr. CAGR % | 71.88 | 79.43 | 31.71 | 53.79 | -15.08 | ||||
EBIT, 3 Yr. CAGR % | 71.88 | 79.43 | 31.71 | 53.79 | -15.08 | ||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -19.71 | 74.48 | -22.25 | 46.38 | -35.99 | ||||
Net Income, 3 Yr. CAGR % | -19.71 | 74.48 | -22.25 | 46.38 | -35.99 | ||||
Normalized Net Income, 3 Yr. CAGR % | 65.23 | 76.35 | 28.05 | 47.81 | -20.52 | ||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -60.19 | 22.15 | -25.97 | 42.17 | -37.91 | ||||
Accounts Receivable, 3 Yr. CAGR % | 44.79 | 46.17 | 30.89 | 1.01 | -23.3 | ||||
Inventory, 3 Yr. CAGR % | 91.27 | 74.85 | 35 | 11.49 | -11.63 | ||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 174.6 | 94.5 | 42.25 | 10.39 | -7.19 | ||||
Total Assets, 3 Yr. CAGR % | 101.62 | 19.31 | 1.27 | -3.39 | 0.4 | ||||
Tangible Book Value, 3 Yr. CAGR % | 52.98 | 25.08 | 0.15 | -4.32 | -2.14 | ||||
Common Equity, 3 Yr. CAGR % | 54.9 | 24.25 | 0.09 | -4.59 | -0.39 | ||||
Cash From Operations, 3 Yr. CAGR % | -34.6 | -0.99 | -58.84 | -32.19 | 59.38 | ||||
Capital Expenditures, 3 Yr. CAGR % | 152.6 | 45.5 | 9.85 | -50.35 | -64.41 | ||||
Levered Free Cash Flow, 3 Yr. CAGR % | 53.98 | 42.56 | 14.93 | -3.72 | 17 | ||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 56.61 | 45.14 | 16.99 | -3.45 | 17.12 | ||||
Compound Annual Growth Rate Over Five Years | |||||||||
Total Revenues, 5 Yr. CAGR % | - | 48.68 | 33.43 | 19.96 | 16.55 | ||||
Gross Profit, 5 Yr. CAGR % | - | 45.6 | 26.76 | 17.54 | 13.08 | ||||
EBITDA, 5 Yr. CAGR % | - | 58.91 | 89.55 | 48.06 | -2.11 | ||||
EBITA, 5 Yr. CAGR % | - | 55.66 | 79.64 | 45.94 | 3.28 | ||||
EBIT, 5 Yr. CAGR % | - | 55.66 | 79.64 | 45.94 | 3.28 | ||||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | 54.66 | 17.79 | 42.34 | -39.62 | ||||
Net Income, 5 Yr. CAGR % | - | 54.66 | 17.79 | 42.34 | -39.62 | ||||
Normalized Net Income, 5 Yr. CAGR % | - | 53.93 | 71.08 | 42.84 | -1.2 | ||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | -2.08 | -23.66 | 13.64 | -42.1 | ||||
Accounts Receivable, 5 Yr. CAGR % | - | 50.85 | 32.53 | 21.36 | -1.69 | ||||
Inventory, 5 Yr. CAGR % | - | 75.97 | 53.78 | 40.33 | 13.46 | ||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | 120.29 | 98.73 | 44.72 | 19.1 | ||||
Total Assets, 5 Yr. CAGR % | - | 68.56 | 50.67 | 8.68 | 2.3 | ||||
Tangible Book Value, 5 Yr. CAGR % | - | 47.23 | 26.76 | 11.65 | 0.35 | ||||
Common Equity, 5 Yr. CAGR % | - | 48.25 | 27.49 | 11.07 | 1.5 | ||||
Cash From Operations, 5 Yr. CAGR % | - | 25.72 | -27.6 | -28.08 | -8.99 | ||||
Capital Expenditures, 5 Yr. CAGR % | - | 103.68 | 50.55 | -21.93 | -30.52 | ||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | 10.78 | 12.71 | 49.04 | ||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | 12.11 | 14.01 | 50.62 |
- Stock Market
- Equities
- TXG Stock
- Financials 10x Genomics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















